

January 10, 2017

BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, <u>MUMBAI - 400 001</u>.

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sirs,

Sub: Investors Presentation.

Pursuant to Regulation 30(2) read with Schedule III Part A(15) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is a copy of the Presentation to be made to Investors at the JP Morgan Healthcare Conference, 2017 scheduled for Tuesday, January 10, 2017 at 2.00 p.m. at San Francisco, USA.

Kindly confirm having received and noted the above.

Thanking you,

Yours faithfully, LIM For LUPIN LIMITED MUMBAI INDIA R. V. SATAM COMPANY SECRETARY

Encl.: a/a

LUPIN LIMITED



LUPIN LIMITED

J.P. Morgan Healthcare Conference January 10th, 2017



This presentation contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection.

The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this report.

Today Lupin is a Globally Dominant Force

Globally




Sources:

- 1. Bloomberg EQS, 31 Dec 2016
- 2. LTM sales available as of 30 Sep 2016


3. IMS MAT Mar 16

- 4. IMS Data Japan (April 2015 March 2016) at NHI price base (including Shionogi brands acquired)
- 5. IMS MAT Sep 16
- 6. IMS MAT Aug 16


A Journey of Stellar Performance




Strong Track Record of Organic & Inorganic Growth




Acquisitions expected to continue to fuel growth across regions




Key Milestones in 2016



Record Growth Across Regions in 1H FY 2017




Thrust on R&D Investment




- Talent pool of 1,700+ scientists at R&D centers across the globe
- 137⁴ ANDA pending filings (33 approvals in 2016); Total market size targeted of \$ 63.3 bn⁵
- 21 pending FTFs; Total market size targeted of \$ 10.5 bn⁶
- R&D capabilities across multiple complex generic verticals, including OCs, Derm, Controlled Substances, Injectables, Inhalation, Biosimilars

Advancing U.S. Inhalation Pipeline



Total Inhalation target market size of ~\$ 18 bn

Global Biosimilar Pipeline



Total Biosimilar target market size of ~\$ 30 bn

Our Strategic Direction



- Primarily a Generic / Branded Generic Business
- 3 strong geographies

2018

- Leading generics player with a larger complex generics and specialty business
- Stronger geographic spread

2020+

- Leading generics player with a significant complex generics and specialty business
- Leading global player

Key Growth Drivers:

- Delivering Complex Generic Pipeline
- Operating / Manufacturing Efficiencies
- Staying Ahead of Compliance Curve
- Commercial Excellence
- Specialty Efforts



Notes

Notes:

- 1. Average exchange rate used for respective years; "mn" indicates million and "bn" indicates billion and correspond to respective fiscal years ending March 31
- 2. Acquisition of remaining stake of Pharma Dynamics
- 3. Gavis acquisition signed July 15, Closed March 16
- 4. As of 31-Dec-16
- 5. IMS MAT Sep 2016
- 6. IMS MAT Nov 2016